• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Movano Health Announces Reverse Stock Split

    10/25/24 9:00:00 AM ET
    $MOVE
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care
    Get the next $MOVE alert in real time by email

    Shares Expected to Begin Trading on Split-Adjusted Basis on October 29, 2024

    PLEASANTON, Calif., Oct. 25, 2024 /PRNewswire/ -- Movano Health (Nasdaq: MOVE) announced today that it will implement a 1-for-15 reverse stock split of the issued shares of its common stock (the "Reverse Stock Split"), effective at 12:01 a.m. Eastern time on October 29, 2024. The Company's common stock is expected to begin trading on a split-adjusted basis when the market opens on Tuesday, October 29, 2024, and will continue to trade on The Nasdaq Capital Market under the symbol "MOVE." The new CUSIP number for the common stock will be 62459M 206.

    (PRNewsfoto/Movano)

    The Reverse Stock Split is intended to increase the bid price of the common stock to enable the Company to regain compliance with the minimum bid price requirement for continued listing on The Nasdaq Capital Market. The Company's stockholders authorized the reverse stock split at the Company's annual meeting of stockholders held on July 9, 2024, with the final ratio subsequently determined by the Company's Board of Directors.

    As a result of the Reverse Stock Split, every 15 shares of the Company's pre-split common stock issued and outstanding will be automatically reclassified into one new share of the Company's common stock. This will reduce the number of shares outstanding from approximately 99.5 million shares to approximately 6.6 million shares. The number of authorized shares of the Company's common stock will remain unchanged. Stockholders who would otherwise be entitled to receive a fractional share will instead automatically have their fractional interests rounded up to the next whole share, after aggregating all the fractional interests of a holder resulting from the Reverse Stock Split. Proportionate adjustments will be made to the exercise prices and the number of shares underlying the Company's equity plans and grants thereunder, as applicable. The Reverse Stock Split will not affect the par value of the common stock.

    The combination of, and reduction in, the issued shares of common stock as a result of the Reverse Stock Split will occur automatically at the effective time of the Reverse Stock Split without any additional action on the part of the Company's stockholders. The Company's transfer agent, Pacific Stock Transfer Company, is acting as the exchange agent for the Reverse Stock Split and will send stockholders of record holding their shares electronically in book-entry form a transaction notice indicating the number of shares of common stock held after the Reverse Stock Split. Stockholders who hold their shares through a broker, bank, or other nominee will have their positions adjusted to reflect the Reverse Stock Split, subject to their broker, bank, or other nominee's particular processes, and are not expected to be required to take any action in connection with the Reverse Stock Split.

    Additional information regarding the Reverse Stock Split can be found in the Company's definitive proxy statement for the annual meeting of stockholders of the Company held on July 9, 2024, which was filed with the U.S. Securities and Exchange Commission on May 28, 2024, a copy of which is available at www.sec.gov and on the Company's website. 

    About Movano Health

    Founded in 2018, Movano Inc. (NASDAQ:MOVE) dba Movano Health, maker of the Evie Ring (www.eviering.com), is developing a suite of purpose-driven healthcare solutions to bring medical-grade data to the forefront of wearables. Featuring modern and flexible form factors, Movano Health's devices offer an innovative approach to delivering trusted data to both customers and enterprises, capturing a comprehensive picture of an individual's health data and uniquely translating it into personalized and intelligent insights.

    Movano Health's proprietary technologies and wearable medical device solutions will soon enable the use of data as a tool to proactively monitor and manage health outcomes across a number of patient populations that exist in healthcare. For more information on Movano Health, visit https://movanohealth.com/.

    Forward Looking Statements

    This press release contains forward-looking statements concerning our expectations, anticipations, intentions, beliefs, or strategies regarding the future. These forward-looking statements are based on assumptions that we have made as of the date hereof and are subject to known and unknown risks and uncertainties that could cause actual results, conditions, and events to differ materially from those anticipated. Therefore, you should not place undue reliance on forward-looking statements. Examples of forward-looking statements include, among others, statements we make regarding plans with respect to the timing and impact of the Reverse Stock Split, the commercial launches of the Evie Ring and EvieMED Ring; our expectations regarding potential commercial opportunities; planned cost-cutting initiatives; anticipated FDA clearance decisions with respect to our products; expected future operating results; product development and features, product releases, clinical trials and regulatory initiatives; our strategies, positioning and expectations for future events or performance. Important factors that could cause actual results to differ materially from those in the forward-looking statements are set forth in our most recent Annual Report on Form 10-K and any subsequent Quarterly Reports on Form 10-Q, and in our other reports filed with the Securities and Exchange Commission, including under the caption "Risk Factors." Any forward-looking statement in this release speaks only as of the date of this release. We undertake no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise.

    Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/movano-health-announces-reverse-stock-split-302286792.html

    SOURCE Movano

    Get the next $MOVE alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Q&A

    New
    • What type of stock split is Movano Health implementing and when will it become effective?

      Movano Health is implementing a 1-for-15 reverse stock split effective at 12:01 a.m. Eastern time on October 29, 2024.

    • Why is Movano Health conducting a reverse stock split?

      The reverse stock split is intended to increase the bid price of the common stock to regain compliance with Nasdaq's minimum bid price requirement.

    • What will be the effect of the reverse stock split on the number of shares outstanding?

      As a result of the reverse stock split, outstanding shares will be decreased from approximately 99.5 million to approximately 6.6 million.

    • What is the new CUSIP number for Movano Health's stock following the reverse stock split?

      The new CUSIP number for Movano Health's common stock will be 62459M 206.

    • Do stockholders need to take any action regarding their shares after the reverse stock split?

      Stockholders will not need to take any action; their holdings will be automatically adjusted, including rounding up fractional shares to the next whole share.

    Recent Analyst Ratings for
    $MOVE

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $MOVE
    SEC Filings

    See more
    • Movano Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Regulation FD Disclosure, Financial Statements and Exhibits

      8-K - Movano Inc. (0001734750) (Filer)

      5/23/25 4:05:24 PM ET
      $MOVE
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • SEC Form NT 10-Q filed by Movano Inc.

      NT 10-Q - Movano Inc. (0001734750) (Filer)

      5/21/25 5:22:02 PM ET
      $MOVE
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Movano Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Other Events

      8-K - Movano Inc. (0001734750) (Filer)

      5/19/25 8:48:13 AM ET
      $MOVE
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    $MOVE
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Movano Health Receives Notification of Deficiency from Nasdaq Related to Delayed Filing of Quarterly Report on Form 10-Q

      PLEASANTON, Calif., May 23, 2025 /PRNewswire/ -- Movano Health (Nasdaq: MOVE)(the "Company") announced today that it received a notice (the "Notice") from the Listing Qualifications Department of the Nasdaq Stock Market ("Nasdaq") indicating that because the Company had not yet filed its Form 10-Q for the quarterly period ended March 31, 2025 (the "Form 10-Q"), the Company was not in compliance with Nasdaq Listing Rule 5250(c)(1) (the "Listing Rule") requiring Nasdaq-listed companies to timely file all periodic financial reports with the Securities and Exchange Commission (the "SEC"). The Form 10-Q was due on May 15, 2025.

      5/23/25 4:05:00 PM ET
      $MOVE
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Movano Health's Board of Directors Initiates Process to Maximize Shareholder Value

      PLEASANTON, Calif., May 16, 2025 /PRNewswire/ -- Movano Health (NASDAQ:MOVE), a pioneer in health technology, announced today that its Board of Directors has initiated a process to explore strategic alternatives, including a sale, merger or similar transaction involving the Company, to maximize shareholder value.  To support this process, Movano Health's Board of Directors has engaged Aquilo Partners as its financial advisor and K&L Gates LLP as its legal counsel. There can be no assurance that this process will result in any transaction or other strategic change or as to the

      5/16/25 4:30:00 PM ET
      $MOVE
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Movano Health's Proprietary Cuffless Blood Pressure Device Once Again Achieves Accuracy Commensurate with the FDA's Requirements

      Leveraging the Company's System-on-a-Chip (SoC), the clinical study results are another significant step forward in commercializing a cuffless, radio frequency (RF)-enabled blood pressure device PLEASANTON, Calif., April 22, 2025 /PRNewswire/ -- Movano Health (NASDAQ:MOVE), a pioneer in health technology, today announced positive results of its most recent 81-participant blood pressure clinical study. Movano Health's prototype demonstrated a level of accuracy well within the standards recognized by the FDA for blood pressure monitoring devices, achieving an overall mean absolute difference (MAD) of 4.9 mmHg, which significantly exceeds the 7 mmHg MAD threshold required per a standard for wea

      4/22/25 8:00:00 AM ET
      $MOVE
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    $MOVE
    Financials

    Live finance-specific insights

    See more
    • Movano Health Reports Q3 2024 Financial Results and Provides Business Update

      Highlights successful Evie Ring back-in-stock execution Updates status of EvieMED 510(k) application review Focuses on launch of EvieMED and securing B2B opportunities Conference Call at 2:00 PM PT/ 5:00 PM ET Today PLEASANTON, Calif., Nov. 14, 2024 /PRNewswire/ -- Movano Health (NASDAQ:MOVE), a pioneer in health technology, reported third quarter 2024 results and provided a business update. The Company continues to remain focused on three key business initiatives. Successful execution of the Evie Ring direct-to-consumer business (D2C) following the September 17th back-in-sto

      11/14/24 4:05:00 PM ET
      $MOVE
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Movano Health Reports Q2 2024 Financial Results and Provides Business Update

      Prepares for September 17, 2024, Evie Ring back in stock dateAnnounces brand partnership with digital creator Heidi D'AmelioFocuses on launch of EvieMED and securing B2B opportunitiesConference Call at 2:00 PM PT/ 5:00 PM ET Today PLEASANTON, Calif., Aug. 14, 2024 /PRNewswire/ -- Movano Health (NASDAQ:MOVE), a pioneer in health technology, reported second quarter 2024 results and provided a business update. Following the successful close of the Company's April 2024 $24.1 million private placement that included a seed investment from a tier 1 multi-billion dollar medical device

      8/14/24 4:05:00 PM ET
      $MOVE
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Movano Health Provides Progress Update on EvieMED Regulatory Filing

      Company continues to work with FDA to bring this pioneering healthcare product to market PLEASANTON, Calif., Aug. 5, 2024 /PRNewswire/ -- Movano Health (Nasdaq: MOVE) plans to meet with the FDA in mid-August, as part of the Company's ongoing process to secure a 510(k) clearance for the EvieMED Ring, a wearable designed to not only provide medical device functionality through its pulse oximetry feature, but also offer numerous wellness metrics related to sleep, activity and mood/energy/symptom logging. On April 21, 2024, Movano Health filed an updated 510(k) for the EvieMED Ring's pulse oximetry feature. At the time of the filing and based on prior interactions with the agency and its protoco

      8/5/24 9:00:00 AM ET
      $MOVE
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    $MOVE
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Caballero Ruben bought 22,000 shares, increasing direct ownership by 38% to 80,200 units (SEC Form 4)

      4 - Movano Inc. (0001734750) (Issuer)

      4/12/24 4:30:19 PM ET
      $MOVE
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Fairbairn Emily bought 4,690,000 shares (SEC Form 4)

      4 - Movano Inc. (0001734750) (Issuer)

      4/4/24 5:30:08 PM ET
      $MOVE
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Cogan Jeremy bought 45,000 shares, increasing direct ownership by 6% to 780,649 units (SEC Form 4)

      4 - Movano Inc. (0001734750) (Issuer)

      4/4/24 5:30:14 PM ET
      $MOVE
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    $MOVE
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Caballero Ruben was granted 43,605 shares, increasing direct ownership by 816% to 48,952 units (SEC Form 4)

      4 - Movano Inc. (0001734750) (Issuer)

      5/13/25 4:30:14 PM ET
      $MOVE
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • CFO Cogan Jeremy was granted 62,986 shares, increasing direct ownership by 121% to 115,028 units (SEC Form 4)

      4 - Movano Inc. (0001734750) (Issuer)

      5/13/25 4:30:12 PM ET
      $MOVE
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Chief Executive Officer Mastrototaro John was granted 77,521 shares, increasing direct ownership by 399% to 96,964 units (SEC Form 4)

      4 - Movano Inc. (0001734750) (Issuer)

      5/13/25 4:30:12 PM ET
      $MOVE
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    $MOVE
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by Movano Inc.

      SC 13G - Movano Inc. (0001734750) (Subject)

      4/10/24 4:39:12 PM ET
      $MOVE
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • SEC Form SC 13G/A filed by Movano Inc. (Amendment)

      SC 13G/A - Movano Inc. (0001734750) (Subject)

      4/9/24 5:41:12 PM ET
      $MOVE
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • SEC Form SC 13G filed by Movano Inc.

      SC 13G - Movano Inc. (0001734750) (Subject)

      2/4/22 4:20:05 PM ET
      $MOVE
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care